

Cover Story
COVID-19 & CancerFreeGuest Editorial
As the crisis triggered by the COVID-19 pandemic deepens, the two separate, unequal societies that make up the United States of America are equally frightened, bewildered, and unsure of what comes next.
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- Columbia’s cancer center becomes collateral damage in Trump’s war on antisemitism
- Caught in the crossfire: The critical threats facing cancer centers, research, and patient care
- Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit
Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology - Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills - What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers